Terminated PHASE1 INTERVENTIONAL 2-arm NCT02875678

A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia

A Single-Dose Study to Evaluate the Effects of ABX-1431 on Gastric Accommodation and Nutrient Volume Tolerance in Patients With Functional Dyspepsia

Sponsor: Abide Therapeutics

Conditions Dyspepsia

Interventions ABX-1431 Placebo

Updated 6 times since 2017 Last updated: Sep 5, 2017 Started: Nov 22, 2016 Primary completion: Aug 7, 2017 Completion: Aug 7, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

recruitment challenges

Other Dyspepsia trials with similar outcome

Browse all Dyspepsia trials

A PHASE1 clinical study on Dyspepsia, this trial is terminated or withdrawn. The trial is conducted by Abide Therapeutics and has accumulated 6 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Oct 2017 — Jun 2018 [monthly]

Terminated PHASE1

Status: Recruiting → Terminated

▶ Show 1 earlier version

Jan 2017 — Oct 2017 [monthly]

Recruiting PHASE1

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abide Therapeutics

Data source: Abide Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leuven, Belgium